Acute myeloid leukemia: open trials in Japan

• NCT07223814

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland

  JP-Bunkyo-Ku-NIPPON, Bunkyō City · JP-Chuo-Ku-CHIBA, Chūōku · JP-Maebashi-Shi-GUNMA, Maebashi · JP-Nagasaki Shi-NAGASAKI, Nagasaki · JP-Nagoya-shi-JRC, Nagoya · JP-Okayama City-OKAYAMA, Okayama · JP-Tokushima Shi-TOKU, Tokushima · JP-Nishi-Gun-YAMAGATA, Yamagata · JP-Yoshida-Gun-FUKUI, Yoshida

  Registry updated 2026-11-06

• NCT06788509

  A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  Trial Treatment · Phase 1 · Janssen Research & Development, LLC

  National Hospital Organization Nagoya Medical Center, Nagoya · The Cancer Institute Hospital of JFCR, Tokyo

  Registry updated 2026-11-04

• NCT06852222

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  Trial Treatment · Phase 3 · Janssen Research & Development, LLC

  Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyō City · Kyushu University Hospital, Fukuoka · Fukushima Medical University Hospital, Fukushima · Gifu Municipal Hospital, Gifu · Kanazawa University Hospital, Kanazawa · Kobe City Medical Center General Hospital, Kobe · National Hospital Organization Kumamoto Medical Center, Kumamoto · Gunmaken Saiseikai Maebashi Hospital, Maebashi · Nagoya University Hospital, Nagoya · Okayama University Hospital, Okayama · Japanese Red Cross Osaka Hospital, Osaka · Aiiku Hospital, Sapporo · Tohoku University Hospital, Sendai · Nippon Medical School Hospital, Tokyo · University of Tsukuba Hospital, Tsukuba · Yamagata University Hospital, Yamagata · University of Fukui Hospital, Yoshida

  Registry updated 2026-11-03

• NCT05429632

  Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  Trial Treatment · Phase 3 · Priothera SAS

  Anjo-kosei Hospital, Anjo-shi · Kyushu University Hospital, Fukuoka · Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima · Kanazawa University Hospital, Kanazawa · Kobe City Medical Center General Hospital, Kobe · Kyoto University Hospital, Kōtoku · Ehime Prefectural Centeral Hospital, Ehime, Matsuyama · Japanese Red Cross Nagoya Daiichi Hospital (First Hospital), Nagoya · Okayama University Hospital, Okayama · Osaka Metropolitan University Hospital, Osaka · Jichi Medical University Saitama Medical Center, Saitama · Hokkaido University Hospital, Sapporo · Jichi Medical University (JMU) Hospital, Shimotsuke-shi · Tokyo Metropolitan Cancer and infection Disese Center Komagome Hospital, Tokyo · Oita University (OU) Hospital, Yufu

  Registry updated 2026-10-30

• NCT07155226

  Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  Trial Treatment · Phase 1/2 · AstraZeneca

  Bunkyō City · Kashiwa · Okayama

  Registry updated 2026-10-23

• NCT06812104

  Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.

  Trial Treatment · Phase 1 · Kyowa Kirin Co., Ltd.

  Kyushu University Hospital, Fukuoka · Fukushima Medical University Hospital, Fukushima · Kansai Medical University Hospital, Hirakata · Kameda General Hospital, Kamogawa · Kanazawa University Hospital, Kanazawa · Kurume University Hospital, Kurume · Dokkyo Medical University Hospital, Mibu · Japanese Red Cross Musashino Hospital, Musashino · Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki · Okayama University Hospital, Okayama · Kindai University Hospital, Osaka · Saitama Medical University Hospital, Saitama · Hokkaido University Hospital, Sapporo · Nippon Medical School Hospital, Tokyo · Toranomon Hospital, Tokyo · Juntendo University Hospital, Tokyo · University of Fukui Hospital, Yoshida

  Registry updated 2026-07-01

• NCT07623616

  A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

  Trial Treatment · Phase 2 · Kyowa Kirin Co., Ltd.

  Chiba Aoba Municipal Hospital, Chiba · Gifu Municipal Hospital, Gifu · Hyogo Medical University Hospital, Hyōgo · Mito Medical Center, Ibaraki · Imamura General Hospital, Kagoshima · Kanagawa Cancer Center, Kanagawa · Kyoto University Hospital, Kyoto · Tohoku University Hospital, Miyagi · Matsumoto National Hospital, Nagano · Nagasaki University Hospital, Nagasaki · Okayama University Hospital, Okayama · Kurashiki Central Hospital, Okayama · Kansai Medical University Hospital, Osaka · Osaka Metropolitan University Hospital, Osaka · Jichi Medical University Saitama Medical Center, Saitama · Jichi Medical University Hospital, Tochigi · Dokkyo Medical University Hospital, Tochigi · Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo · Keio University Hospital, Tokyo · Nippon Medical School Hospital, Tokyo

  Registry updated 2026-06-03

• NCT07604064

  A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

  Trial Treatment · Phase 2 · Kissei Pharmaceutical Co., Ltd.

  Tokyo and Other Japanese Cities

  Registry updated 2026-05-27

• NCT04988555

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  Trial Treatment · Phase 1/2 · Sumitomo Pharma America, Inc.

  Tokyo Metropolitan Komagome Hospital, Bunkyō City · Nippon Medical School Hospital, Bunkyo-ku · Kyushu University Hospital, Fukuoka · Fukushima Medical University Hospital, Fukushima · Hokkaido University Hospital, Hokkaido · Tokai University Hospital, Isehara-Shi · National Cancer Center Hospital East, Kashiwa-shi · Tohoku University Hospital, Miyagi · Nagasaki University Hospital, Nagasaki · Okayama University Hospital, Okayama · Osaka University Hospital, Osaka · University of Fukui Hospital, Yoshida-gun

  Registry updated 2026-03-24

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error